Nicox presents NCX 470 Phase 3 data at AAOpt annual meeting

• Nicox will present Phase 3 data on glaucoma drug candidate NCX 470 at the AAOpt Annual Meeting in Anaheim, Sept. 30-Oct. 3, 2026.
• Key presentations are scheduled for Oct. 1, 2026, including Denali U.S. subgroup results versus latanoprost and aqueous humor dynamics findings.
• Conference participation also includes Investor Access in Paris on Oct. 6-7, 2026, followed by the AAO meeting in New Orleans on Oct. 9-12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160130PRIMZONEFULLFEED1001262877) on September 16, 2026, and is solely responsible for the information contained therein.